AG
CRVS icon

Artal Group’s Corvus Pharmaceuticals CRVS Stock Holding History

Artal Group’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-500,000
Closed -$1.15M – 108
2023
Q2 		$1.15M Hold
500,000
– – 0.04% 90
2023
Q1 		$455K Hold
500,000
– – 0.03% 105
2022
Q4 		$425K Hold
500,000
– – 0.02% 116
2022
Q3 		$409K Hold
500,000
– – 0.02% 126
2022
Q2 		$495K Hold
500,000
– – 0.03% 123
2022
Q1 		$820K Hold
500,000
– – 0.03% 129
2021
Q4 		$1.21M Hold
500,000
– – 0.04% 137
2021
Q3 		$2.42M Buy
+500,000
New +$1.48M 0.06% 131

Other funds holding CRVS

O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
SC
Samlyn Capital New York $5.82B AUM 36.3% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TL
TowerView LLC New York $155M AUM 30.14% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $121B AUM 33.93% 1-Year Est. Return